Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024

LONDON, March 21, 2014 /PRNewswire/ --

Stem  cell  developers  and  producers  -  discover  companies'  R&D  and  revenue  prospects

Who are the top stem cell developers and producers? And what are their sales potentials? Visiongain's new report shows you their outlooks from 2014. There you discover therapies, sales results, trends, opportunities, and predictions of revenues.

That way you find data and analysis on cellular technologies with potential to improve human medicine. Our study analyses 22 leading companies in the US, Europe, Israel, and Asia. There you hear how stem cell producers can gain and progress, discovering what's possible.

Read on to see those organisations and find what their market could be worth.

Forecasts  and  other  data  helping  you  stay  ahead  for  those  technologies  and  applications

In our new study you find analytical profiles of 22 stem cell companies, and analyses of that overall industry. So you see results, research and development (R&D), growth rates, and revenue forecasting. Discover, from 2014, those firms' commercial prospects.

There you also gain 106 tables, 38 charts, and two interviews with companies.

See now how you can benefit your research, analyses, and decisions, also saving time and helping your influence for those treatments. The following sections explain.

Company  profiles  -  activities,  competition,  and  operational  outlooks

The contents of company profiles differ, but our study covers details such as these:
•    Technologies, R&D pipelines, products, and financial performance
•    Acquisitions, alliances, technological applications, and clinical developments
•    Strengths, weaknesses, opportunities, and threats to business (SWOT forces)
•    Revenues to 2024 (stem cell forecasts for 18 companies).

Discover there what participants do, provide, and seek, helping you stay ahead. You assess how they can perform to 2024.

That new investigation divides the industry into three regional blocks.

To see an exec summary of this report please email Sara Peerun on sara.eerun@visiongainglobal.com

United  States  (US)  -  leading  organisations  and  their  potentials

First our study gives you discussions, financial analyses, and commercial outlooks for 10 US-based stem cell firms, including these:
•    Advanced Cell Technology (ACT)
•    BrainStorm Cell Therapeutics
•    Bioheart
•    International Stem Cell Corporation (ISCO)
•    NeoStem
•    Osiris Therapeutics.

There you hear what the future holds for those healthcare companies, including trends and revenue predictions to 2024.

The report then analyses Europe and Israel, showing that region's activities and potential.

Companies  based  in  Europe  and  Israel  -  what  successes  can  they  achieve?

Next our analysis shows you progress and revenue outlooks to 2024 for 7 European and Israeli companies, including these:
•    apceth
•    Cardio3 BioSciences
•    Cell Cure Neurosciences
•    TiGenix
•    Gamida Cell
•    Pluristem Therapeutics.

Our work shows you where sales growth can occur. Many opportunities remain in that industry, with high, expanding revenues possible from this decade. There you see where sales occur and what they mean. You also explore plans for launching products.

That study then analyses the Asian segment, explaining its potential.

Stem  cell  specialists  based  in  the  Asia-Pacific  region

You also discover outlooks for 5 top researchers, developers, and producers of stem cells in Asia:
•    Anterogen
•    MEDIPOST
•    Mesoblast
•    Pharmicell
•    Stempeutics Research.

Our report shows potentials of that industry segment. You see possibilities for advancing technology and raising business performance, assessing where money lies.

That study also covers the overall world industry, showing you its revenue potential.

To see an exec summary of this report please email Sara Peerun on sara.eerun@visiongainglobal.com

Predictions  for  the  worldwide  stem  cells  market  -  what's  possible  by  2018  and  beyond?

Our report also forecasts revenues to 2024 for the overall world stem cells industry and five submarkets:
•    Cancer treatment (oncology)
•    Cardiovascular (CV) applications
•    Central nervous system (CNS) uses
•    Other therapy using those biological agents
•    Non-therapeutic cellular products.

There you find overall revenues reaching $12.2bn in 2018, with high growth to 2024. You also examine forces driving and restraining that industry - social, technological, economic, and political issues.

See, then, what the future holds for those technological advances.

Technologies  shaping  the  stem  cells  industry  and  market  -  explore  progress  and  potential

Our study explains those cellular technologies and their benefits. You explore these advances and many others:
•    Human embryonic stem cells - aiding tissue repair and regeneration
•    Autologous and allogeneic agents, including T cell therapy (T lymphocytes)
•    Genetically-modified treatment for cancer
•    Cell engraftment in bone marrow transplantation
•    Umbilical cord blood - applications of that tissue and cell banking
•    Non-therapeutic pharma applications - cellular screening in drug development.

There you also get interviews with companies, finding information to help you stay ahead on commercial progress, outlooks, and future trends. That way, avoid missing out.

Ways  Pharma  Leader  Series:  Top  Stem  Cell  Technology  Companies  2014-2024  helps

In particular, our new investigation gives you this knowledge to benefit your work:
•    Profiles of 22 leading companies in North America, Europe, Israel, and Asia - assess products, R&D progress, results, strategies, and partnerships
•    Revenues to 2024 for that market at world level and by submarket - discover potential sales, seeing the commercial possibilities
•    Competition, needs, and opportunities - explore what affects the stem cells industry, finding what influences participants' sales and determines their futures
•    Interviews with developers and producers of stem cells - find what participants from that industry think, say, and do, helping you stay ahead.

Information  there  found  nowhere  else,  benefiting  your  understanding,  work  and  authority

Our report gives independent data. There you get competitive intelligence found only in that work, finding where progress and money lie. You examine the commercial possibilities.

With that original research and analysis you're less likely to fall behind in information or miss opportunity. There see how you could save time and effort. And benefit your plans, decisions, and influence, helping gain competitive advantages.

So by trying our new analysis on stem cells you explore trends, R&D, and sales predictions. Avoid missing out - please get that report here now.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on http://www.visiongain.com/Report/1223/Pharma-Leader-Series-Top-Stem-Cell-Technology-Companies-2014-2024

Companies  Listed  in  this  report:

Aastrom Biosciences
Advanced Cell Technology (ACT)
African-Middle East Medical (AFRIMID)
Alkem Laboratories
AlloCure
Alphatec Spine
Amorcyte
Anosis
Anterogen
Antria
Apceth
Athelos Corporation
Athersys
Axiogenesis
Becton-Dickinson
BioCardia
BioE
Biogenea Pharmaceuticals
Bioheart
Biomet Orthopedics
BioTime
Bluebird Bio
BrainStorm Cell Therapeutics
California Stem Cell Inc.
Capricor Therapeutics
Cardio3 BioSciences
Cell Cure Neurosciences
Cell Line Genetics
Cellectis
Cellerant Therapeutics
Celltex Therapeutics
Cellular Dynamics International
CHA Bio & Diostech
Cipla
Cognate BioServices
Cook General BioTechnology
Cryo-Cell International
Cryo-Save
Cytomedix
Cytori Therapeutics
DaVinci Biosciences
Dendreon
Dong-A Pharmaceutical
Drug Controller General of India
Epistem
ERCell LLC
European Medicines Agency (EMA)
Fibrocell Science
Food and Drug Administration (FDA)
Forticell Bioscience
Gamida Cell
Garnet BioTherapeutics
Genzyme
Geron
GlobalStem
Hadassah University Hospital
Harvard Medical School
Health Canada
Human Stem Cells Institute
Immunocellular Therapeutics
Intellicell BioSciences
Intercytex
International Stem Cell Corporation (ISCO)
Intrexon Corporation
Invitrx Therapeutics
InVivo Therapeutics
iPierian
Jules Stein Eye Institute
King's College London
Lentigen
Lifeline Skin Care
Lincoln Park Capital Fund
Lonza
MEDIPOST
Medistem
Merck & Co.
Merck Millipore
Mesoblast
National Academy of Engineering (Korea)
NeoStem
Neuralstem
NeuroGeneration
Novartis
NuVasive
Office of the Chief Scientist (Israel)
OncoCyte
OncoMed Pharma
Orgenesis
OrthoCyte
Osiris Therapeutics
OvaScience
Pharmicell
Plasticell Therapeutics
Pluristem Therapeutics
Progenitor Cell Therapy
Proneuron Biotechnologies
Ramot
ReCyte Therapeutics
Regen BioPharma
Regenerative Sciences
RegenoCELL Therapeutics
ReNeuron
RhinoCyte
Roslin Cellab
Rush University Medical Center
SanBio
Saneron CCEL Therapeutics
Sanofi
Schepens Eye Research Institute
South Korea Food and Drug Administration (SFDA)
Stem Cell Medicine
Stem Cell Sciences
StemCells
Stemcyte
Stemedica Cell Technologies
Stemline Therapeutics
Stempeutics Research
Stratatech Corporation
Targazyme (formerly America Stem Cell, Inc.)
TCA Cellular Therapy
Technology Strategy Board (UK)
Tel Aviv University
Teva Pharmaceuticals
The Isar Medical Centre
TiGenix
Tissue Genesis
United Therapeutics
US Department of Defence
US National Academy of Sciences
Vesta Therapeutics
ViaCyte
VistaGen
Vital Therapies
Vitro Biopharma
Wizbang Technologies
World Health Organization (WHO)

To see an exec summary of this report please email Sara Peerun on sara.eerun@visiongainglobal.com